MARIETTA, Ga., July 7, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that Dr. I. Mark Landy has joined MiMedx as the Company's Vice President responsible for key strategic initiatives.
Parker H. "Pete" Petit, Chairman and CEO, said, "In his new role, Mark will report to me and support certain domestic and international strategic imperatives and related growth initiatives. We are very pleased to have Mark become part of the MiMedx team, and we look forward to the many contributions he will make to our strategic and tactical planning. Mark has a wide array of experience, including holding senior roles in institutional healthcare equity research and investing and C-Level executive roles in the drug delivery/medical device sector of the healthcare industry. Mark has unique and extremely valuable expertise that will add momentum to a number of critical initiatives we have underway and others that are in the planning stages."
Bill Taylor, President and COO, commented, "Mark is extremely knowledgeable about our industry sector and has developed an outstanding reputation within the investment community for his in-depth research and insights. He combines fifteen years of Wall Street expertise with seven years of industry executive experience and clinical practice experience. With Mark's understanding of the investment community, we will also rely on his expertise to support various investor relations initiatives."
Immediately prior to joining MiMedx, Dr. Landy was Managing Director and Senior Research Analyst – Biopharmaceuticals and Medical Technology at Northland Capital Markets / Summer Street Research Partners. Before his tenure with Northland Capital Markets, Dr. Landy was President and Chief Executive Officer at MIV Therapeutics, Inc., a global leader in developing polymer-free drug delivery systems for cardiovascular stents and other implantable devices. Prior to MIV, he held various senior analyst positions at several investment banking firms.
Dr. Landy holds a Bachelor of Business Administration from The Wharton School of Business, University of Pennsylvania, and a Doctor of Dental Surgery from the University of the Witwatersrand, Johannesburg, South Africa.
MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies are AmnioFix®, EpiFix®, OrthoFlo, Physio®, AlloBurn™, and CollaFix™. AmnioFix and EpiFix are our tissue technologies processed from human amniotic membrane derived from donated placentas. Elected in advance of delivery through our donor program, a mother delivering a healthy baby via scheduled full-term Caesarean section birth may donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx is the leading supplier of amniotic tissue, having supplied over 600,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. We recently introduced OrthoFlo, an amniotic fluid derived allograft for homologous use. Amniotic fluid is donated by a consenting mother delivering a full-term healthy baby by scheduled Caesarean section. Through the recent acquisition of Stability Biologics, our newest proprietary platforms include Physio, a unique bone grafting material comprised of 100% bone tissue with no added carrier, thus maximizing bone forming potential, a demineralized bone matrix (DBM) to complement our product portfolio offerings within the Orthopedic market and AlloBurn, a skin product for burns. CollaFix, our next technology platform we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair. CollaFix is the only biological, biodegradable, biomimetic technology that matches human tendon in strength and stiffness. The Company's wholly-owned subsidiary, Stability Biologics, LLC, is accredited by the American Association of Tissue Banks (AATB) and registered with the FDA. The Company distinguishes its revenue in two primary regenerative medicine specialties of "Wound Care" and "SSO." The Company defines SSO as surgical, sports medicine and orthopedics with spinal procedures included in orthopedics and abdominal, and lower pelvic procedures included in surgical.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mimedx-adds-new-executive-300295245.html
SOURCE MiMedx Group, Inc.